Phar21 Ch. 1

Front 1

Acute respiratory distress syndrome

Back 1

Respiratory disorder characterized by respiratory insufficiency that may occur as a result of trauma pneumonia oxygen toxicity gram-negative sepsis and systemic inflammatory response

Front 2

Aerosolized agents

Back 2

Group of aerosol drugs for pulmonary applications that includes adrenergic anticholinergic vehicle active corticosteroid anti asthmatic an anti-infective agent and surfactant instilled directly into the trachea

Front 3

Airway Resistance

Back 3

Measure of the impedance to ventilation caused by the movement of gas through the airway

Front 4

Trade name or brand name

Back 4

Or proprietary name given to a drug by a particular manufacturer

Front 5

Chemical name

Back 5

Name indicating the chemical structure of a drug

Front 6

Chronic obstructive pulmonary disease

Back 6

Disease process characterized by airflow limitation that is not fully reversible is usually Progressive and associated with an abnormal inflammatory response of the lung to not just particles or gases diseases that cause airflow limitation include chronic bronchitis emphysema asthma and bronchiectasis

Front 7

Code name

Back 7

Name assigned by a manufacturer to an experimental chemical that shows potential as a drug and examples aerosol SCH 1100 name for a proprium bromide a parasympatholytic bronchodilator

Front 8

Cystic fibrosis

Back 8

Inherited disease of exocrine glands affecting the pancreas respiratory system and April crime glands symptoms usually begin in infancy and are characterized by increased electrolytes in the sweat chronic respiratory infection and pancreatic insufficiency

Front 9

Drug Administration

Back 9

Method by which a drug is made available to the body

Front 10

Generic name

Back 10

Name assigned to a chemical by the United States adopted name Council when the chemical appears to have therapeutic use and the manufacturer wishes to market a drug

Front 11

Non-proprietary name

Back 11

Name of a drug other than its trademark name

Front 12

Official name

Back 12

In the event that an experimental drug becomes fully approved for General use and is admitted to the United States pharmacopeia national formulary the generic name becomes the official name

Front 13

Orphan drug

Back 13

Drug or biologic product for the diagnosis or treatment of a rare disease affecting fewer than 200,000 persons in the United States

Front 14

Pharmacodynamics

Back 14

Mechanisms of drug action by which a drug molecule causes its effect in the body

Front 15

Pharmacogenetics

Back 15

Study of the interrelationship of genetic differences and drug effects

Front 16

Pharmacognosy

Back 16

Identification of sources of drugs from plants and animals

Front 17

Pharmacokinetics

Back 17

Time course and disposition of a drug in the body face on its absorption distribution metabolism and elimination

Front 18

Pharmacology

Back 18

Study of drugs or chemicals including their Origins properties and interactions with living organisms

Front 19

Pharmacy

Back 19

Preparation and dispensing of drugs

Front 20

Pneumocystis jiroveci

Back 20

Organism causing pneumocystis pneumonia in humans seen in immunosuppressed individuals such as those infected with human immunodeficiency virus HIV

Front 21

Prescription

Back 21

In order for a drug along with any specific instructions for compounding dispensing and taking the drug this order may be written by physician osteopath dentist veterinarian and others but not by chiropractors are opticians

Front 22

Pseudomonas aeruginosa

Back 22

Gram-negative organism from Reynosa Camille pathogen that causes urinary tract infections respiratory system infections dermatitis soft tissue infections bacteremia Bone and Joint infections gastrointestinal infections and various systemic infections particularly in patients with severe burns and patients who are immunosuppressed

Front 23

Respiratory Care pharmacology

Back 23

Application pharmacology to the treatment of pulmonary disorders and more broadly Critical Care

Front 24

Respiratory syncytial virus

Back 24

Virus that causes the formation of syncytial masses in cells this leads to inflammation of the bronchioles which may cause respiratory distress

Front 25

Therapeutics

Back 25

Art of treating disease with drugs

Front 26

Toxicology

Back 26

Study of toxic substances and their pharmacologic actions including antidotes and poison control